Bristol-Myers Squibb says late-stage study of Opdivo in lung cancer hits main goal
Bristol-Myers Squibb announced that a Phase III trial of the anti-PD1 immune checkpoint inhibitor Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced, squamous cell non-small-cell lung cancer (NSCLC) was stopped early after meeting its endpoint.
The company indicated that the CheckMate-017 trial's independent Data Monitoring Committee concluded that Opdivo demonstrated superior overall survival compared to docetaxel. Bristol-Myers Squibb noted that results "for the first time indicate a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer."
The study randomised 272 patients with advanced or metastatic squamous cell NSCLC to receive either Opdivo or docetaxel. The trial's main goal is overall survival, while secondary endpoints include objective response rate and progression-free survival. Bristol-Myers Squibb said that it will share the data with health authorities.
January 12th, 2015
By: Matthew Dennis